A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Orexigen Therapeutics, Inc
ClinicalTrials.gov Identifier:
NCT00456521
First received: April 3, 2007
Last updated: December 2, 2014
Last verified: December 2014

April 3, 2007
December 2, 2014
March 2007
December 2008   (final data collection date for primary outcome measure)
  • Co-primary: Body Weight- Mean Percent Change [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
  • Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
Change from baseline to week 56 in percentage of total body weight lost
Complete list of historical versions of study NCT00456521 on ClinicalTrials.gov Archive Site
  • Body Weight- Proportion of Subjects With ≥10% Decrease [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
  • Change in Waist Circumference [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
  • Change in Fasting Triglycerides Levels, Using Log-transformed Data [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
  • Change in Fasting Insulin Levels, Using Log-transformed Data [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
  • Change in Fasting HDL Cholesterol Levels [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
  • Change in IWQOL-Lite Total Scores [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
    IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment
  • Change in HOMA-IR Levels, Using Log-transformed Data [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
    HOMA-IR= Homeostasis Model Assessment-Insulin Resistance
  • Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
  • Change in Fasting Blood Glucose Levels [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
  • Change in Fasting LDL Cholesterol [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
  • Change in Systolic Blood Pressure [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
  • Change in Diastolic Blood Pressure [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
  • Change in IDS-SR Total Scores [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: Yes ]
    IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.
  • Change in Food Craving Inventory Sweets Subscale Scores [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
    The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).
  • Change in Food Craving Inventory Carbohydrates Subscale Scores [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
    The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).
  • Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire [ Time Frame: Baseline, 56 weeks ] [ Designated as safety issue: No ]
    Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult
  • Proportion of subjects who lose at least 5% and 10% of their baseline body weight
  • Effects on mood from baseline to week 56 as measured by the IDS-SR
  • Effect on selected obesity-associated cardiovascular risk factors, including serum triglycerides, HDL and LDL cholesterol, waist circumference, glucose and insulin levels, HOMA-IR, hs-CRP levels and vital signs.
  • Effects on quality of life from baseline to week 56 as measured by the IWQOL- Lite
Not Provided
Not Provided
 
A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion SR and Placebo in Subjects With Obesity Participating in a Behavior Modification Program

The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in treating obesity and leads to greater weight loss when given with a group lifestyle modification program than with group lifestyle modification alone.

The combination of group lifestyle modification counseling and pharmacotherapy has recently been shown to result in nearly twice the average weight loss at one year (12.1 kg) as pharmacotherapy alone (sibutramine, 5.0 kg) or lifestyle modification counseling alone (6.7 kg). Combining pharmacotherapy with a comprehensive program of diet, exercise and group lifestyle modification counseling may provide the best weight loss regimen. This study evaluated weight loss in subjects participating in such a comprehensive program who received a combination of naltrexone SR and bupropion SR, or placebo.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Obesity
  • Overweight
  • Drug: Naltrexone SR 32 mg/ bupropion SR 360 mg/ day
    Other Name: NB32
  • Drug: Placebo
  • Behavioral: Intensive group lifestyle modification counseling
  • Experimental: NB32
    Naltrexone SR 32 mg/ bupropion SR 360 mg/ day with intensive group lifestyle modification counseling
    Interventions:
    • Drug: Naltrexone SR 32 mg/ bupropion SR 360 mg/ day
    • Behavioral: Intensive group lifestyle modification counseling
  • Placebo Comparator: Placebo
    Placebo with intensive group lifestyle modification counseling
    Interventions:
    • Drug: Placebo
    • Behavioral: Intensive group lifestyle modification counseling
Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011 Jan;19(1):110-20. doi: 10.1038/oby.2010.147. Epub 2010 Jun 17.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
793
December 2008
December 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female or male subjects aged 18 to 65 years (inclusive)
  • Body mass index (weight [kg]/height [m²]) ≥30 and ≤45 kg/m² for subjects with uncomplicated obesity, and BMI of ≥27 and ≤45 kg/m² for subjects with controlled hypertension and/or dyslipidemia
  • Non-smoker and had not used tobacco or nicotine products for at least 6 months before screening
  • Normotensive (systolic ≤140 mm Hg and diastolic ≤90 mm Hg). Anti-hypertensive medications were allowed with the exception of alpha-adrenergic blockers, beta-blockers, and clonidine. Medical regimen was to be stable for at least 8 weeks.
  • Low-density lipoprotein level <190 mg/dL and triglycerides level <400 mg/dL. Medications for the treatment of dyslipidemia were allowed as long as the medical regimen had been stable for at least 8 weeks.
  • No clinically significant abnormality of serum albumin, blood urea nitrogen (BUN), creatinine, bilirubin, calcium and phosphorus
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 2.5 times upper limit of normal (ULN)
  • No clinically significant abnormality of hematocrit, white blood cell (WBC) count, WBC differential, or platelets
  • Fasting glucose ≤126 mg/dL and not receiving hypoglycemic agents
  • No clinically significant abnormality on urinalysis
  • Thyroid stimulating hormone (TSH) within 1.5 times ULN or normal triiodothyronine (T3), if TSH was below normal limits
  • Female subjects of childbearing potential had a negative serum pregnancy test
  • An IDS-SR score <2 on individual items: 5 (sadness), 6 (irritability), 7 (anxiety/tension), and 18 (suicidality) and an IDS-SR total score <30
  • Female subjects of childbearing potential were non-lactating and agreed to continue to use effective contraception throughout the study and 30 days after discontinuation of study drug
  • Completed a food diary for 6 of 7 consecutive days during screening
  • Able to comply with all required study procedures and schedule
  • Able to speak and read English
  • Provided written informed consent

Exclusion Criteria:

  • Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome, established polycystic ovary syndrome)
  • Serious medical condition (including but not limited to renal or hepatic insufficiency; congestive heart failure, angina pectoris, myocardial infarction, stroke, claudication, or acute limb ischemia; history of malignancy with exception of non-melanoma skin cancer or surgically cured cervical cancer)
  • Serious psychiatric illness (e.g., lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, and anorexia nervosa; current serious personality disorder, e.g., borderline; severe major depressive disorder, recent [previous 6 months] suicide attempt or current active suicidal ideation, recent hospitalization due to psychiatric illness)
  • Response to the bipolar disorder questions that indicated the presence of bipolar disorder.
  • Required medications for the treatment of a psychiatric disorder (with the exception of short-term insomnia) within the previous 6 months
  • History of drug or alcohol abuse or dependence within 1 year
  • Type I or Type II diabetes mellitus
  • Baseline ECG with a corrected QT (QTc) interval (using Bazett's formula >450 millisecond (msec) [males] and >470 msec [females]) or the presence of any clinically significant cardiac abnormalities, including but not limited to patterns consistent with myocardial ischemia, electrolyte abnormalities, or atrial or ventricular dysrhythmia or significant conduction abnormalities
  • Received excluded concomitant medications: any psychotropic agents (including antipsychotic, antidepressant, anxiolytic, mood stabilizer or anticonvulsant agents) with the exception of low-dose benzodiazepine or hypnotic agents for the treatment of insomnia; any anorectic or weight loss agents; any over-the-counter dietary supplements with psychoactive, appetite or weight effects; alpha-adrenergic blockers; beta-blockers; clonidine; coumadin; theophylline; cimetidine; oral corticosteroids; topiramate, Depo-Provera®; smoking cessation agents; regular use of opioid or opioid-like analgesics
  • History of surgical or device (e.g., lap band) intervention for obesity
  • History of seizures of any etiology, or of predisposition to seizures (e.g., history of cerebrovascular accident, head trauma with >5 minutes loss of consciousness, concussion symptoms lasting >15 minutes, brain surgery, skull fracture, subdural hematoma, or febrile seizures)
  • History of treatment with bupropion or naltrexone within the preceding 12 months
  • History of hypersensitivity or intolerance to bupropion or naltrexone
  • Used drugs, herbs, or dietary supplements believed to significantly affect body weight or participated in a weight loss management program within one month prior to baseline
  • Loss or gained >4.0 kilograms within the previous 3 months
  • Females who were pregnant or breast-feeding or planning to become pregnant during the study period or within 30 days of discontinuing study drug
  • Planned surgical procedure that could impact the conduct of the study
  • Received any investigational drug or used an experimental device or procedure within the previous 30 days
  • Participated in any previous clinical trial conducted by Orexigen
  • Had any condition that in the opinion of the investigator made the subject unsuitable for inclusion into the study
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00456521
NB-302, COR-BMOD
Yes
Orexigen Therapeutics, Inc
Orexigen Therapeutics, Inc
Not Provided
Not Provided
Orexigen Therapeutics, Inc
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP